Protease receptor antagonism to target blood platelet therapies
M Holinstat, PF Bray - Clinical Pharmacology & Therapeutics, 2016 - Wiley Online Library
M Holinstat, PF Bray
Clinical Pharmacology & Therapeutics, 2016•Wiley Online LibraryPlatelet activation and thrombus formation play a central role in ischemic vascular disease.
Thrombin, an especially potent physiologic agonist mediating in vivo activation of platelets,
acts via a unique family of G‐protein‐coupled receptors called protease‐activated receptors
(PARs) with a broad tissue expression. This review focuses on current antiplatelet therapies
as well as innovative approaches to targeting PARs in patients with atherothrombotic
vascular disease.
Thrombin, an especially potent physiologic agonist mediating in vivo activation of platelets,
acts via a unique family of G‐protein‐coupled receptors called protease‐activated receptors
(PARs) with a broad tissue expression. This review focuses on current antiplatelet therapies
as well as innovative approaches to targeting PARs in patients with atherothrombotic
vascular disease.
Platelet activation and thrombus formation play a central role in ischemic vascular disease. Thrombin, an especially potent physiologic agonist mediating in vivo activation of platelets, acts via a unique family of G‐protein‐coupled receptors called protease‐activated receptors (PARs) with a broad tissue expression. This review focuses on current antiplatelet therapies as well as innovative approaches to targeting PARs in patients with atherothrombotic vascular disease.
Wiley Online Library